

09/757,011

=> d his

search of applicants
Species

(FILE 'HOME' ENTERED AT 09:46:52 ON 12 SEP 2003)

FILE 'CPLUS' ENTERED AT 09:46:59 ON 12 SEP 2003

L1 33 S OGNYANOV V?/AU
L2 48 S BORDEN L?/AU
L3 1071 S BELL S?/AU
L4 24877 S ZHANG J?/AU
L5 4 S L1 AND L2 AND L3 AND L4
L6 4 S L5 AND PATENT/DT
L7 1 S US6191165/PN
L8 1 S L6 AND L7
SELECT RN L8 1-

FILE 'REGISTRY' ENTERED AT 09:48:05 ON 12 SEP 2003

L9 200 S E1-200
L10 168 S E201-368
L11 368 S L9 OR L10
L12 60 S L11 AND NRS=1
L13 286 S L11 AND NRS>1
L14 346 S L12 OR L13
L15 22 S L11 NOT L14

FILE 'CPLUS' ENTERED AT 09:50:02 ON 12 SEP 2003

FILE 'REGISTRY' ENTERED AT 09:50:14 ON 12 SEP 2003

L16 10 S L12 AND GLYCINE
L17 2 S L16 AND DIBENZO
L18 1 S L16 AND FLUOREN
L19 1 S L16 AND ETHANO?
L20 290 S L13 OR L17 OR L18 OR L19

FILE 'CPLUS' ENTERED AT 09:56:06 ON 12 SEP 2003

L21 9601 S L20
L22 ANALYZE L21 1- RN HIT : 290 TERMS

FILE 'REGISTRY' ENTERED AT 10:03:46 ON 12 SEP 2003

L23 4 S 54910-89-3/RN OR 92-69-3/RN OR 451-40-1/RN OR 1083-30-3/RN
L24 6 S 19812-93-2/RN OR 2128-93-0/RN OR 712-50-5/RN OR 5586-73-2/RN
L25 280 S L20 NOT (L23 OR L24)

FILE 'CPLUS' ENTERED AT 10:06:24 ON 12 SEP 2003

L26 1311 S L25
L27 ANALYZE L26 1- RN HIT : 280 TERMS

FILE 'REGISTRY' ENTERED AT 10:10:20 ON 12 SEP 2003

L28 7 S 53179-07-0/RN OR 29558-77-8/RN OR 644-13-3/RN OR 39634-42-9/R
L29 3 S 27064-94-4/RN OR 22679-54-5/RN OR 39186-58-8/RN
L30 270 S L25 NOT (L28 OR L29)

FILE 'CPLUS' ENTERED AT 10:11:33 ON 12 SEP 2003

L31 282 S L30
L32 ANALYZE L31 1- RN HIT : 270 TERMS

FILE 'REGISTRY' ENTERED AT 10:13:33 ON 12 SEP 2003

L33 5 S 6305-20-0/RN OR 2168-06-1/RN OR 23808-47-1/RN OR 3311-94-2/RN
L34 5 S 14984-21-5/RN OR 32501-12-5/RN OR 6078-95-1/RN OR 49757-42-8/

09/757,011

L35 260 S L30 NOT (L33 OR L34)

FILE 'CAPLUS' ENTERED AT 10:14:24 ON 12 SEP 2003

L36 17 S L35
L37 12 S L36 AND PATENT/DT
L38 5 S L36 NOT L37
L39 0 S L38 AND 2003/SO
L40 2 S L38 AND 2002/SO
L41 0 S L38 AND 2000/SO
L42 0 S L38 AND 1999/SO
L43 0 S L38 AND 1998/SO
L44 15 S L36 NOT L40

=> d ibib abs hitstr 1-15


09/757,011

L44 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 PRIORITY NUMBER: 2003:610460 CAPLUS
 DOCUMENT NUMBER: 139:165080
 TITLE: Catalyst activators containing Group 13 elements and heteroatom group for ethylene/.alpha.-olefin copolymerization
 INVENTOR(S): Holtcamp, Matthew W.
 PATENT ASSIGNEE(S): Univation Technologies, LLC, USA
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064433	A1	20030807	WO 2002-US40743	20021218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, HA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW	M: MW, SD, SL, SZ, TZ, UG, ZM, ZW	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG	Y: ZA, ZW	US 2002-5857 A 20020128

PRIORITY APPLN. INFO.: US 2002-5857 A 20020128
 GI

L44 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 (prep. of catalyst activators for ethylene/.alpha.-olefin copolymer.)
 RN 200004-38-2 CAPLUS
 CN Benzene, 1,1',1'''-(bromomethylidyne)tris[4-fluoro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



AB A olefin polymn. catalyst system comprises a metallocene catalyst and a catalyst activator having a formula $\text{Cat}^+[\text{M}(\text{JY})_x]^-$, where M = a Group 13 element, e.g. B or Al; (JY) = a heterocyclic group, J = a Group 15 or 16 heteroatom contained in Y, x = the valence of M + 1, Cat⁺ = a cation component. The heteroatom group (JY) is represented by the formula I, where X2-X7 is independently selected from H, halogen, an alkyl group, a halogenated or partially halogenated alkyl group, an aryl group, a halogenated or partially halogenated aryl group, an aryl substituted alkyl or a halogenated or partially halogenated aryl substituted alkyl group.

IT 200004-38-2

RL: RCT (Reactant), RACT (Reactant or reagent)

L44 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 PRIORITY NUMBER: 2003:5918 CAPLUS
 DOCUMENT NUMBER: 138:56244
 TITLE: Preparation of sarcosine aromatic ether derivatives as inhibitors of glycine transport
 INVENTOR(S): Lowe, John Adams, III
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000646	A1	20030103	WO 2002-IB1513	20020412
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, HA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW	M: MW, SD, SL, SZ, TZ, UG, ZM, ZW	AT, BE, CH, CY, DE, DK, ES, FI, FR, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG	Y: ZA, ZW	US 2003013887 A1 20030116 US 2002-86037 20020228 US 6566550 B2 20030520

PRIORITY APPLN. INFO.: US 2001-299827P P 20010621
 OTHER SOURCE(S): MARPAT 138:56244
 GI


L44 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 3-phenyl-3-[4-(3-(trifluoromethyl)phenoxy]phenoxy]-1-chloropropane (prep. given), followed by ester cleavage. Compds. I show significant activity in inhibiting glycine re-uptake in synaptosomes (IC50 values more potent than 10 μM).

IT 200005-62-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prep. of sarcosine arom. ether derivs. as inhibitors of glycine transport)


RN 200005-62-5 CAPLUS
 CN Glycine, N-methyl-N-(3-phenyl-3-[4-(4-(trifluoromethyl)phenoxy)phenoxy]propyl)-, hydrochloride (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




AB Substituted arom. ethers I [A is a ring (Ph, naphthyl, benzothienyl, benzofuranyl, pyridyl, mono- or bicyclic (hetero)aryl not containing adjacent ring oxygen atoms); X, Y are alkyl, fluoroalkyl, alkoxy, fluoroalkoxy, carboxy, carboalkoxy, carboxamido, alkylthio, sulfonyl, sulfonyl, halo, nitro, cyano, amino, alkylamino, or dialkylamino; B is alkyl, fluoroalkyl, alkoxy, fluoroalkoxy, or halo] or their pharmaceutically-acceptable salts were prep. as glycine transport inhibitors for use in the enhancement of cognition and the treatment of the pos. and neg. symptoms of schizophrenia and other psychoses in mammals, including humans. Thus, [methyl(3-phenyl-3-[4-(3-(trifluoromethyl)phenoxy)phenoxy]propyl)amino]acetic acid was prep. by alkylation of sarcosine Et ester hydrochloride with




RN 200004-66-6 CAPLUS
CN Glycine, N-(3-(1,1'-biphenyl)-4-yl-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-67-7 CAPLUS
CN Glycine, N-(3-(1,1'-biphenyl)-4-yl-3-phenylpropyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-70-2 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(4-(trifluoromethyl)phenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-71-3 CAPLUS
CN Glycine, N-[3-phenyl-3-(4-(trifluoromethyl)phenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-77-9 CAPLUS
CN Glycine, N-[(3R)-3-((1,1'-biphenyl)-4-yloxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 200004-78-0 CAPLUS
CN Glycine, N-[(3S)-3-((1,1'-biphenyl)-4-yloxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 200004-79-1 CAPLUS
CN Glycine, N-(3-(4-(1,1-dimethylethyl)phenoxy)-3-phenylpropyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-80-4 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-73-5 CAPLUS
CN Glycine, N-(3-(4-(1,1-dimethylethyl)phenoxy)-3-(4-fluorophenyl)propyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-74-6 CAPLUS
CN Glycine, N-methyl-N-(3-((6-methyl-3-pyridinyl)oxy)-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-75-7 CAPLUS
CN Glycine, N-[3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-76-8 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(1,1,3,3-tetramethylbutyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-81-5 CAPLUS
CN Glycine, N-[3-(4-phenoxyphenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-84-8 CAPLUS
CN Glycine, N-[3-(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-87-1 CAPLUS
CN Glycine, N-methyl-N-[3-(2-naphthalenyl)oxy]-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-88-2 CAPLUS
CN Glycine, N-methyl-N-[3-(1-naphthalenyl)oxy]-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN Glycine, N-[3-((1,1'-biphenyl)-4-yloxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-96-2 CAPLUS
 CN Glycine, N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-05-6 CAPLUS
 CN Glycine, N-[3-(4-chlorophenyl)-3-(4-cyanophenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-07-8 CAPLUS
 CN Glycine, N-[3-(4-chlorophenyl)-3-phenoxypropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-08-9 CAPLUS
 CN Glycine, N-[3-(4-fluorophenyl)-3-(4-methoxyphenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-34-1 CAPLUS
 CN Glycine, N-[3-(3,3-diphenylpropyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 200005-41-0 CAPLUS
 CN Glycine, N-[3-hydroxy-3-phenyl-3-(2-thienyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-42-1 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-(2-thienyl)-2-propenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-46-5 CAPLUS
 CN Glycine, N-[3-(4-methoxyphenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-49-8 CAPLUS
 CN Glycine, N-[3-((1,1-dimethylethyl)phenylthio)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-11-4 CAPLUS
 CN Glycine, N-methyl-N-((3R)-3-(4-nitrophenoxy)-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 200005-17-0 CAPLUS
 CN Glycine, N-methyl-N-((3R)-3-(4-nitrophenoxy)-3-phenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200005-24-9 CAPLUS
 CN Acetonitrile, [(methyl(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)amino)- (9CI) (CA INDEX NAME)




RN 200005-32-9 CAPLUS
 CN Phosphonic acid, [(methyl(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)amino)- (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200005-51-2 CAPLUS
 CN Glycine, N-((3R)-3-((4-(1,1-dimethylethyl)phenoxy)-3-phenylpropyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 200005-52-3 CAPLUS
 CN Glycine, N-((4,4-diphenyl-3-butenyl)-N-ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-54-5 CAPLUS
 CN Glycine, N-((4,4-diphenylbutyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-00-4 CAPLUS
 CN Glycine, N-[3-(1-naphthalenyl)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200006-07-1 CAPLUS
 CN Glycine, N-[(3S)-3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 200006-08-2 CAPLUS
 CN Glycine, N-[(3R)-3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



● HCl

RN 200006-09-3 CAPLUS
 CN Glycine, N-[(3R)-3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



● HCl

RN 200006-10-6 CAPLUS
 CN Glycine, N-[(3R)-3-(4-fluorophenyl)-3-(4-tricyclo[3.3.1.13,7]dec-1-ylphenoxy)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




● HCl

RN 200006-24-2 CAPLUS
 CN 2-Azetidinecarboxylic acid, 1-(4,4-diphenyl-3-butenyl)-, methyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200006-25-3 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-50-4 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[3-(4-chlorophenyl)-3-(4-fluorophenyl)-3-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 76991-05-4P 200004-41-7P 200004-45-1P
 200004-46-2P 200004-47-3P 200004-48-4P
 200004-49-5P 200004-50-8P 200004-57-5P
 200004-60-0P 200004-63-3P 200004-64-4P
 200004-65-5P 200004-69-9P 200004-72-4P
 200004-83-7P 200004-85-9P 200004-86-0P
 200004-89-3P 200004-91-7P 200004-92-8P
 200004-93-9P 200004-94-0P 200004-95-1P
 200004-97-3P 200004-98-4P 200004-99-5P
 200005-00-1P 200005-01-2P 200005-02-3P
 200005-03-4P 200005-04-5P 200005-06-7P
 200005-09-0P 200005-10-3P 200005-12-5P
 200005-13-6P 200005-14-7P 200005-15-8P
 200005-16-9P 200005-18-1P 200005-19-2P
 200005-21-6P 200005-22-7P 200005-23-8P
 200005-25-0P 200005-26-1P 200005-27-2P
 200005-28-3P 200005-29-4P 200005-30-7P
 200005-31-8P 200005-33-0P 200005-35-2P
 200005-36-3P 200005-37-4P 200005-38-5P
 200005-39-6P 200005-40-9P 200005-43-2P
 200005-44-3P 200005-45-4P 200005-47-6P
 200005-48-7P 200005-50-1P 200005-53-4P
 200005-55-6P 200005-56-7P 200005-57-8P
 200005-58-9P 200005-59-0P 200005-60-3P
 200005-61-4P 200005-62-5P 200005-63-6P
 200005-64-7P 200005-65-8P 200005-66-9P
 200005-67-0P 200005-68-1P 200005-69-2P
 200005-70-5P 200005-71-6P 200005-72-7P
 200005-73-8P 200005-74-9P 200005-75-0P
 200005-76-1P 200005-77-2P 200005-78-3P
 200005-79-4P 200005-80-7P 200005-81-8P
 200005-82-9P 200005-83-0P 200005-84-1P
 200005-85-2P 200005-86-3P 200005-87-4P
 200005-88-5P 200005-89-6P 200005-90-9P
 200005-91-0P 200005-92-1P 200005-93-2P
 200005-94-3P 200005-95-4P 200005-96-5P
 200005-97-6P 200005-98-7P 200005-99-8P
 200006-01-5P 200006-02-6P 200006-03-7P
 200006-04-8P 200006-05-9P 200006-06-0P
 200006-11-7P 200006-12-8P 200006-22-0P
 200006-23-1P 200006-27-5P 200006-28-6P
 200006-29-7P 200006-30-0P 200006-31-1P
 200006-33-3P 200006-35-5P 200006-37-7P
 200006-39-9P 200006-40-2P 200006-42-4P

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 200006-44-6P 200006-46-8P 200006-48-0P
 200006-52-6P 200006-54-8P 200006-56-0P
 200006-58-2P 200006-60-6P 200006-63-3P
 200006-85-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of amino acid derivs. as pharmaceuticals for treatment of neural, and neuropsychiatric disorders)
 RN 76991-05-4 CAPLUS
 CN Acetamide, 2-[(3,3-diphenylpropyl)amino]- (9CI) (CA INDEX NAME)




RN 200004-41-7 CAPLUS
 CN L-Alanine, N-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200004-45-1 CAPLUS
 CN D-Alanine, N-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200004-46-2 CAPLUS
 CN Glycine, N,N-bis[2-(9H-fluoren-9-yl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 200004-50-8 CAPLUS
 CN Glycine, N-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200004-57-5 CAPLUS
 CN Glycine, N-(3,3-bis([1,1'-biphenyl]-4-yl)propyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-60-0 CAPLUS
 CN Glycine, N,N-bis[3-(2-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-63-3 CAPLUS
 CN Glycine, N-[3-[(1,1-dimethylethyl)phenyl]-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-64-4 CAPLUS
 CN Glycine, N-methyl-N-(3,3,3-triphenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-47-3 CAPLUS
 CN Glycine, N-[4,4-bis(4-fluorophenyl)butyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 200004-48-4 CAPLUS
 CN Glycine, N-(3,3-bis(4-fluorophenyl)propyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-49-5 CAPLUS
 CN Glycine, N-(3-cyano-3-diphenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 200004-65-5 CAPLUS
 CN Glycine, N,N-bis(3-[1,1'-biphenyl]-4-yl-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-69-9 CAPLUS
 CN Glycine, N-(3,4-diphenyl-3-butenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-72-4 CAPLUS
 CN Glycine, N-[3,3-bis(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-83-7 CAPLUS
 CN Glycine, N-[3-[(4-bromo[1,1'-biphenyl]-4-yl)oxy]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-85-9 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[3-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-09-0 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-phenoxypropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-10-3 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-[(trifluoromethyl)phenoxy]propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-12-5 CAPLUS
CN Glycine, N-[(3S)-3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




CN Benzeneepropanamine, γ -gamma-((1,1'-biphenyl)-4-yloxy)-N-(2,2-dimethoxyethyl)-4-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 200005-18-1 CAPLUS
CN Glycine, N-[2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)ethyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-19-2 CAPLUS
CN Glycine, N-[3-(5H-dibenzo[a,d]cyclohepten-5-yl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-21-6 CAPLUS
CN Glycine, N-[3-(9,10-ethanoanthracen-9(10H)-yl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-22-7 CAPLUS


RN 200005-13-6 CAPLUS
CN Glycine, N-((3R)-3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200005-14-7 CAPLUS
CN Glycine, N-((3R)-3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200005-15-8 CAPLUS
CN Glycine, N-((3R)-3-(4-fluorophenyl)-3-(4-tricyclo[3.3.1.13,7]dec-1-ylphenoxy)propyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




CN Glycine, N-((3R)-3-(2-methoxyphenoxy)-3-phenylpropyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-23-8 CAPLUS
CN Glycine, N-methyl-N-(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)-propyl ester (9CI) (CA INDEX NAME)




RN 200005-25-0 CAPLUS
CN Glycine, N-methyl-N-(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)-phenyl ester (9CI) (CA INDEX NAME)




RN 200005-26-1 CAPLUS
CN Acetamide, N-ethyl-2-[methyl(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)amino]- (9CI) (CA INDEX NAME)




RN 200005-27-2 CAPLUS
CN Acetamide, N,N-diethyl-2-[methyl(3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl)amino]- (9CI) (CA INDEX NAME)




RN 200005-28-3 CAPLUS
CN Glycine, N-methyl-N-(2-methyl-3-(1-oxopropoxy)-3,4-diphenylbutyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-29-4 CAPLUS
CN Glycine, N-(3-hydroxy-2-methyl-3,4-diphenylbutyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-30-7 CAPLUS
CN Acetamide, 2-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)




RN 200005-31-8 CAPLUS
CN Morpholine, 4-[(methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino)methyl]sulfonyl- (9CI) (CA INDEX NAME)




RN 200005-33-0 CAPLUS
CN Glycine, N-[3-(1-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-35-2 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)




RN 200005-36-3 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 200005-37-4 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, octyl ester (9CI) (CA INDEX NAME)




RN 200005-38-5 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 200005-39-6 CAPLUS


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 200005-40-9 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 200005-43-2 CAPLUS
CN Glycine, N-[3-(2-furanyl)-3-hydroxy-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-44-3 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(2-thienyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-45-4 CAPLUS
CN Glycine, N-methyl-N-(3-phenoxyl-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-47-6 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(phenylthio)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-48-7 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenyl]thio]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-50-1 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(phenylamino)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-53-4 CAPLUS
CN Glycine, N-(3,3-diphenylpropyl)-N-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 200005-55-6 CAPLUS
CN Glycine, N-(4,4-diphenylbutyl)-N-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 200005-56-7 CAPLUS
CN Glycine, N-(4,4-diphenylbutyl)-N-ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-57-8 CAPLUS
CN Glycine, N-(4,4-diphenyl-3-butenyl)-, hydrochloride (9CI) (CA INDEX NAME)

Ph₂C=CH-CH₂-NH-CH₂-CO₂H

● HCl

RN 200005-58-9 CAPLUS


CN Glycine, N-(4,4-diphenylbutyl)-, hydrochloride (9CI) (CA INDEX NAME)

Ph₂CH-(CH₂)₃-NH-CH₂-CO₂H

● HCl

RN 200005-59-0 CAPLUS


CN Glycine, N-[3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-60-3 CAPLUS

CN Glycine, N-(3-cyclohexyl-3-phenylpropyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl



● HCl

RN 200005-65-8 CAPLUS


CN Glycine, N-methyl-N-(3,3,3-tris(4-chlorophenyl)propyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200005-66-9 CAPLUS

CN Glycine, N-methyl-N-(3-(2-naphthalenyl)-3-phenylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-67-0 CAPLUS


CN Glycine, N-[3-((1,1'-biphenyl)-4-yloxy)-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

CN Glycine, N-methyl-N-[3-phenyl-3-[(4-(1,1,3,3-tetramethylbutyl)phenoxy)propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

CN Glycine, N-methyl-N-[3-phenyl-3-[(4-(trifluoromethyl)phenoxy)phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

CN Glycine, N-[3-(4-(1,1-dimethylethyl)phenoxy)-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

CN Glycine, N-[3-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-3-phenylpropyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

CN Glycine, N-[3-[(4-(1,1-dimethylethyl)phenyl)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


CN Glycine, N-(3-(1,1'-biphenyl)-4-yl-3-phenylpropyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


CN Glycine, N-methyl-N-[3-phenyl-3-(phenylthio)propyl]-, hydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 200005-71-6 CAPLUS
CN Glycine, N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-72-7 CAPLUS
CN Glycine, N-[3-(4-chlorophenyl)-3-(4-cyanophenoxy)propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-73-8 CAPLUS
CN Glycine, N-[3-(4-chlorophenyl)-3-phenoxypropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-77-2 CAPLUS
CN Glycine, N-[3-[(4-(1,1-dimethylethyl)phenyl)thio]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-78-3 CAPLUS
CN Glycine, N-[(3R)-3-[(1,1'-biphenyl)-4-yloxy]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl


RN 200005-79-4 CAPLUS
CN Glycine, N-methyl-N-[3-(4-phenoxyphenoxy)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-74-9 CAPLUS
CN Glycine, N-methyl-N-[(3R)-3-(4-nitrophenoxy)-3-phenylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl



RN 200005-75-0 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-76-1 CAPLUS
CN Glycine, N-[(3R)-3-[4-(1,1-dimethylethyl)phenoxy]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 200005-80-7 CAPLUS
CN Glycine, N-[3,3-bis(4-phenoxyphenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-81-8 CAPLUS
CN Glycine, N-methyl-N-[3-(1-naphthalenyl)oxy]-3-phenylpropyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-82-9 CAPLUS
CN Glycine, N-(3,5-diphenylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-96-5 CAPLUS
 CN Glycine, N-[3,3-bis(3-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-97-6 CAPLUS
 CN Glycine, N-[3,3-bis([1,1'-biphenyl]-4-yl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-98-7 CAPLUS
 CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenyl]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-03-7 CAPLUS
 CN Glycine, N-(3-[1,1'-biphenyl]-4-yl-3-phenylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-04-8 CAPLUS
 CN Glycine, N-[3-phenyl-3-[4-(trifluoromethyl)phenyl]propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-05-9 CAPLUS
 CN Glycine, N-[3-(4-fluorophenyl)-3-(4-methoxyphenoxy)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-99-8 CAPLUS
 CN Phosphonic acid, [(methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-01-5 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenyl]thio]propyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-02-6 CAPLUS
 CN Glycine, N-methyl-N-[3-(4-nitrophenoxy)-3-phenylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-06-0 CAPLUS
 CN Glycine, N-methyl-N-[3,3-tris(4-fluorophenyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-11-7 CAPLUS
 CN 1H-1,2,4-Triazole-3-methanamine, N-(3,3-diphenylpropyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)





● x HCl


RN 200006-12-8 CAPLUS
 CN Glycine, N-(3,3-diphenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 200006-22-0 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-[4,4-bis(4-fluorophenyl)butyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-23-1 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-[2-(9H-fluoren-9-yl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-27-5 CAPLUS
CN L-Proline, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200006-33-3 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-(3,3-diphenylpropyl)-, methyl ester, (1R,2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 200006-35-5 CAPLUS
CN L-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200006-37-7 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-(4,4-diphenyl-3-but enyl)-, methyl ester, (1R,2R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 200006-39-9 CAPLUS
CN 1H-Indole-2-carboxylic acid, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-28-6 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-29-7 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(3,3-diphenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-30-0 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-31-1 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(4,4-diphenylbutyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-40-2 CAPLUS
CN 2-Azetidinocarboxylic acid, 1-(4,4-diphenyl-3-but enyl)-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 200006-42-4 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-44-6 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-[3,3-bis(4-fluorophenyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-46-8 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(3-hydroxy-3,3-diphenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-49-0 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-[3-(4-methoxyphenoxy)-3-phenylpropyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-52-6 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200006-54-8 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(3-phenoxy-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-85-5 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-[3-(4-chlorophenyl)-3-(4-fluorophenyl)-2-propenyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 101781-30-0 200004-38-2 200006-13-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of amino acid derivs. as pharmaceuticals for treatment of
neurol. and neuropsychiatric disorders)

RN 101781-30-0 CAPLUS
CN Benzeneethanol, .alpha.-[1-methyl-2-(methylamino)ethyl]-.alpha.-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200004-38-2 CAPLUS
CN Benzene, 1,1',1'''-(bromomethylidyne)tris[4-fluoro- (9CI) (CA INDEX NAME)




RN 200006-13-9 CAPLUS
CN 1-Naphthalenepropanamine, .gamma.-phenyl- (9CI) (CA INDEX NAME)


RN 200006-56-0 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-[3-(4-methoxyphenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)





RN 200006-59-2 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-[3-phenyl-3-(phenylthio)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200006-60-6 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-[3-(4-chlorophenyl)-3-hydroxy-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-83-3 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 21763-01-9P 64723-43-9P 63584-90-1P
200003-86-7P 200003-88-9P 200003-89-2P
200003-90-3P 200003-91-4P 200003-92-5P
200003-93-6P 200003-94-7P 200003-95-8P
200003-96-9P 200003-97-0P 200003-98-1P
200003-99-2P 200004-00-8P 200004-01-9P
200004-02-0P 200004-03-1P 200004-04-2P
200004-05-3P 200004-06-4P 200004-07-5P
200004-08-6P 200004-09-7P 200004-10-0P
200004-11-1P 200004-12-2P 200004-13-3P
200004-14-4P 200004-15-5P 200004-16-6P
200004-17-7P 200004-18-8P 200004-19-9P
200004-20-2P 200004-22-4P 200004-23-5P
200004-24-6P 200004-25-7P 200004-26-8P
200004-27-9P 200004-28-0P 200004-29-1P
200004-30-4P 200004-31-5P 200004-32-6P
200004-33-7P 200004-34-8P 200004-35-9P
200004-36-0P 200004-37-1P 200006-17-3P
200006-20-8P 200006-21-9P 200006-72-0P
200006-74-2P 200006-76-4P 200006-78-6P
200006-80-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of amino acid derivs. as pharmaceuticals for treatment of
neurol. and neuropsychiatric disorders)


RN 21763-01-9 CAPLUS
CN Benzene, (3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)




RN 64723-43-9 CAPLUS
CN 9H-Fluorene-9-ethanol, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 83584-90-1 CAPLUS
 CN Benzenepropanol, .gamma.,.gamma.-diphenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-86-7 CAPLUS
 CN Benzenepropanol, 4-fluoro-.gamma.-(4-fluorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-89-9 CAPLUS
 CN Benzenepropanol, 4-fluoro-.gamma.,.gamma.-bis(4-fluorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-92-5 CAPLUS
 CN Benzenepentanol, .gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-93-6 CAPLUS
 CN Benzenepropanol, 4-phenoxy-.gamma.-(4-phenoxyphenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-94-7 CAPLUS
 CN [1,1'-Biphenyl]-4-propanol, .gamma.-(1,1'-biphenyl)-4-yl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-95-8 CAPLUS
 CN Benzenepropanol, 4-(1,1-dimethylethyl)-.gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-89-0 CAPLUS
 CN Benzenepropanol, .gamma.-cyclohexyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-90-3 CAPLUS
 CN Benzenepropanol, 4-methoxy-.gamma.,.gamma.-bis(4-methoxyphenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-91-4 CAPLUS
 CN Benzenepropanol, 3-fluoro-.gamma.-(3-fluorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-96-9 CAPLUS
 CN Benzenepropanol, 4-chloro-.gamma.,.gamma.-bis(4-chlorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)



RN 200003-97-0 CAPLUS
 CN 2-Naphthalenepropanol, .gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-99-1 CAPLUS
 CN [1,1'-Biphenyl]-4-propanol, .gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-99-2 CAPLUS
 CN 1,4-Butanediol, 1,2-diphenyl-, 4-(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 20004-00-8 CAPLUS
CN Benzenepropanol, 3, gamma.-phenyl-4-(trifluoromethyl)-, 4-
methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 20004-01-9 CAPLUS
CN Benzene, 1-[3-chloro-1-[4-(1,1-dimethylethyl)phenoxy]propyl]-4-fluoro-
(9CI) (CA INDEX NAME)



RN 20004-02-0 CAPLUS
CN Pyridine, 5-(3-chloro-1-phenylpropoxy)-2-methyl- (9CI) (CA INDEX NAME)




RN 20004-03-1 CAPLUS
CN 1,1'-Biphenyl, 4-[3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX
NAME)




RN 20004-04-2 CAPLUS


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 20004-09-7 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-phenoxy- (9CI) (CA INDEX NAME)




RN 20004-10-0 CAPLUS
CN 1,1'-Biphenyl, 4-bromo-4'-(3-chloro-1-(4-fluorophenyl)propoxy)- (9CI) (CA
INDEX NAME)




RN 20004-11-1 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 4'-(3-chloro-1-phenylpropoxy)- (9CI) (CA
INDEX NAME)




RN 20004-12-2 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-3-(trifluoromethyl)- (9CI) (CA
INDEX NAME)




RN 20004-13-3 CAPLUS
CN Naphthalene, 2-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)

L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(1,1,3,3-tetramethylbutyl)- (9CI)
(CA INDEX NAME)


RN 20004-05-3 CAPLUS
CN 1,1'-Biphenyl, 4-[(1R)-3-chloro-1-phenylpropoxy]- (9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (+).



RN 20004-06-4 CAPLUS
CN 1,1'-Biphenyl, 4-[(1S)-3-chloro-1-phenylpropoxy]- (9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (-).




RN 20004-07-5 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(1,1-dimethylethyl)- (9CI) (CA
INDEX NAME)




RN 20004-08-6 CAELUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(4-(trifluoromethyl)phenoxy)-
(9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 20004-14-4 CAPLUS
CN Naphthalene, 1-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 20004-15-5 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-methyl- (9CI) (CA INDEX NAME)



RN 20004-16-6 CAPLUS
CN 1,1'-Biphenyl, 4-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 20004-17-7 CAPLUS
CN Benzenesulfonamide, 4-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 20004-18-8 CAPLUS


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-nitro- (9CI) (CA INDEX NAME)




RN 200004-19-9 CAPLUS
 CN Benzene, 4-(3-chloro-1-phenylpropoxy)-1-nitro-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 200004-20-2 CAPLUS
 CN Benzonitrile, 4-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 200004-22-4 CAPLUS
 CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 200004-23-5 CAPLUS
 CN Benzene, 1-(3-chloro-1-[4-(trifluoromethyl)phenoxy]propyl)-2,4-dimethoxy- (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN Benzonitrile, 4-[3-chloro-1-(4-chlorophenyl)propoxy]- (9CI) (CA INDEX NAME)




RN 200004-29-1 CAPLUS
 CN Benzene, 1-bromo-4-[3-chloro-1-(4-chlorophenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 200004-30-4 CAPLUS
 CN Benzene, 1-chloro-4-(3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)



RN 200004-31-5 CAPLUS
 CN Benzene, 1-(3-chloro-1-(4-fluorophenyl)propoxy)-4-methoxy- (9CI) (CA INDEX NAME)




RN 200004-32-6 CAPLUS
 CN Benzene, 1-(3-chloro-1-phenoxypropyl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 200004-33-7 CAPLUS
 CN Benzene, 1-(3-chloro-1-(4-fluorophenyl)propoxy)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-24-6 CAPLUS
 CN 1,3-Benzodioxole, 5-[3-chloro-1-(4-chlorophenyl)propoxy]- (9CI) (CA INDEX NAME)




RN 200004-25-7 CAPLUS
 CN Benzene, 1-bromo-4-(3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)



RN 200004-26-8 CAPLUS
 CN Benzene, 1-bromo-4-[3-chloro-1-(4-(trifluoromethyl)phenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 200004-27-9 CAPLUS
 CN Benzene, 1-chloro-4-[3-chloro-1-(4-methoxyphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 200004-28-0 CAPLUS


L44 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-34-8 CAPLUS
 CN Benzene, 1-[1R)-3-chloro-1-phenylpropoxy]-4-nitro- (9CI) (CA INDEX NAME)
 Absolute stereochemistry. Rotation (+).




RN 200004-35-9 CAPLUS
 CN 1,1'-Biphenyl, 4-[1S)-3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry. Rotation (-).




RN 200004-36-0 CAPLUS
 CN 1,1'-Biphenyl, 4-[1R)-3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry. Rotation (+).



RN 200004-37-1 CAPLUS
 CN Tricyclo[3.3.1.13,7]decane, 1-[4-(1R)-3-chloro-1-(4-fluorophenyl)propoxy]phenyl- (9CI) (CA INDEX NAME)
 Absolute stereochemistry. Rotation (+).




RN 200006-17-3 CAPLUS
CN Glycine, N-methyl-N-[3-[(4-methylphenyl)sulfonyl]phenylamino]-3-phenylpropyl-, ethyl ester (9CI) (CA INDEX NAME)





RN 200006-20-8 CAPLUS
CN Acetonitrile, [(3,3-diphenylpropyl)amino]- (9CI) (CA INDEX NAME)

Ph₂CH-CH₂-CH₂-NH-CH₂-CN


RN 200006-21-9 CAPLUS
CN Acetonitrile, [(3,3-diphenylpropyl)methylamino]- (9CI) (CA INDEX NAME)



RN 200006-72-0 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(3-oxo-3-phenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




IT 200006-19-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of amino acid derivs. as pharmaceuticals for treatment of
neurol. and neuropsychiatric disorders)
RN 200006-19-5 CAPLUS
CN Benzenepropanaminium, N-(2-ethoxy-2-oxoethyl)-N,N-dimethyl-.gamma.-(4-(trifluoromethyl)phenoxy)-, iodide (9CI) (CA INDEX NAME)




REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


RN 200006-74-2 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-[3-(4-fluorophenyl)-3-oxopropyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-76-4 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(3-oxo-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 200006-78-6 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(3-hydroxy-3-phenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-80-0 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(3-chloro-3-phenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2000:157915 CAPLUS

DOCUMENT NUMBER: 132:194656

TITLE: Preparation of proline derivatives and related compounds as GABA uptake inhibitors

INVENTOR(S): Wanner, Klaus; Fuelep, Guenther; Hoefner, Georg

PATENT/ASSIGNEE(S): Germany

SOURCE: Ger. Offen., 36 pp.

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19840611	A1	20000309	DE 1998-19840611	19980905
CA 2343531	AA	20000316	CA 1999-2343531	19990903
WO 2000014064	A2	20000316	WO 1999-EP6486	19990903
WO 2000014064	A3	20000720		
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, TR, US, ZA RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
AU 9959726	A1	20000327	AU 1999-59726	19990903
EP 1109783	A2	20010627	EP 1999-968664	19990903
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002524443	T2	20020806	JP 2000-568823	19990903
PRIORITY APPLN. INFO.:			DE 1998-19840611 A	19980905
			WO 1999-EP6486	W 19990903

OTHER SOURCE(S): HARPAT 132:194656

GI




AB Title compds. [I]; R1-R7 = H, OH, halo, cyano, alkyl, alkenyl, alkynyl, (substituted) aryl, heteroaryl, etc.; R1R2 and/or R3R4 and/or R5R6 = (substituted) alkylidene, O or pairs of adjoining R1-R7 = double bonds; X = CO₂H group physiol. convertible to CO₂M; M = H, pharmaceutically acceptable cation; Z = Y3CO, Y2C:CR15, Y2C:NO; R15 = H, alkyl, halo; Y = (substituted) aryl, heteroaryl; A1 = (CR8R9)_n, (substituted) alkylene, or a combination thereof; n = gtoreq.2; R8, R9 = H, alkyl, halo, OH, etc.; A2 = (CR10R11)_m; R10, R11 = H, alkyl, halo; m = gtoreq.2, were prep'd. as GABA uptake inhibitors (no data). Thus, L-proline Me ester hydrochloride (prep'd. given), KI, K₂CO₃, and 4,4-diphenylbut-3-en-1-yl bromide were stirred 46 h in acetone to give 5.4% Me (S)-N-(4,4-diphenylbut-3-en-1-yl)pyrrolidine-2-carboxylate.

IT RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L44 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
(prep. of proline derivs. and related compds. as GABA uptake
inhibitors)
RN 200006-35-5 CAPLUS
CN L-Proline, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX
NAME)



Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
ACCESSION NUMBER: 1999:106960 CAPLUS
DOCUMENT NUMBER: 130:218300
TITLE: Aminomethyl-substituted cyclic amines as microsomal
triglyceride transfer protein inhibitors and
pharmaceuticals containing them
INVENTOR(S): Inoue, Satoshi; Hirao, Yuzo; Yokomoto, Masaharu;
Tamura, Koichi; Amano, Hirotaka; Ueda, Chikusa
PATENT ASSIGNEE(S): Wakunaga Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKKOAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11035555	A2	19990209	JP 1997-196899	19970723
PRIORITY APPLN. INFO.:		JP 1997-196899	19970723	
OTHER SOURCE(S):		MARPAT 130:218300		
GI				



AB Pharmaceuticals, useful for prevention and treatment of hyperlipidemia or
arteriosclerosis, contain title compds. I [R1 = COR4, SO2R4, R2 = H,
(substituted) alkyl, (hetero)aryl, (hetero)alkyl; R1R2 = Q1; R3 =
(substituted) (hetero)alkyl, N-arylcarbamoylalkyl, di(hetero)arylsalkyl,
arylcycloalkylalkyl, (hetero)arylsalkenyl, Q2; R4 = (substituted)
(cycle)alkyl, (hetero)aryl (hetero)alkyl; ring Ar1 = arom. ring; Z =
CH5, CO, SO2; R5 = H, alkyl A = single bond, CH2, (CH2)2, -CH=CHO-, S; R6
= H, alkyl, CO2H, (substituted) N-alkylcarbamoyl ring Ar2, Ar3 = benzene,
pyridine, thiophene, or furan ring; X = CH7, O; R7 = H, silyl; m = 1, 2;
n = 1-3; 1 = 1-7] or their salts. 4'-Trifluoromethylbiphenyl-2-carboxylic
acid (190 mg) was chlorinated by COCl2 in CHCl3-DMF, amidated with 350 mg


L44 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
N-(2,2,2-trifluoroethyl)-9-[4-(2-(aminomethyl)morpholino)butyl]-9H-
fluorene-9-carboxamide (prep. given) and Et3N in CHCl3 at room temp. for
2 h, and treated with HCl to give 120 mg N-(2,2,2-trifluoroethyl)-9-[4-(2-
[(4'-(trifluoromethyl)biphenyl-2-yl)carbonylaminomethyl)morpholino]butyl]-
9H-fluorene-9-carboxamide.HCl, which in vitro inhibited secretion of apoB
lipoprotein from human HepG2 cells with IC50 of 0.0150 μM.

IT 200003-66-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(prep. of aminomethyl-substituted cyclic amines as microsomal
triglyceride transfer protein inhibitors)


RN 200003-66-7 CAPLUS

CN Benzene propanol, 4-fluoro-.gamma.-(4-fluorophenyl)-, 4-
methylbenzenesulfonate (9CI) (CA INDEX NAME)



L44 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
ACCESSION NUMBER: 1998:304147 CAPLUS
DOCUMENT NUMBER: 128:322090
TITLE: Catalyst systems for (co)polymerization of
.alpha.-olefins
INVENTOR(S): Sanchez Royo, Jose; Munoz-Escalona Lafuente, Antonio;
Pena Garcia, Begona; Martin, Marcos Carlos
PATENT ASSIGNEE(S): Repsol Quimica S.A., Spain
SOURCE: Eur. Pat. Appl., 12 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 839833	A2	19980506	EP 1997-500184	19971030
EP 839833	A3	19980902		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 970498	A	19980504	NO 1997-4998	19971030
NO 9705017	A	19980504	NO 1997-5007	19971030
NO 9705008	A	19980504	NO 1997-5008	19971030
JP 10182416	A2	19980707	JP 1997-336262	19971030
JP 10226710	A2	19980802	JP 1997-336261	19971030
JP 3352374	B2	20021203		
JP 10226711	A2	19980825	JP 1997-336263	19971030
JP 3340064	B2	20021028		
US 5977392	A	19991102	US 1997-961349	19971030
AT 189822	E	20000315	AT 1997-500186	19971030
ES 2142140	T3	20000401	ES 1997-500186	19971030
ES 2158474	T3	20010901	ES 1997-500185	19971030
PRIORITY APPLN. INFO.:		ES 1996-2302		
OTHER SOURCE(S):		MARPAT 128:322090		
GI				



AB Compds. I [M = transition metal of Groups 3, 4-10 of the periodic table of
the elements, lanthanide, actinide; X = H, halo, (un)substituted
(cyclo)alkyl, aryl, etc.; L = neutral Lewis base; A = ring with
delocalized pi electrons, that directly coordinates to the transition
metal M; E = BR2, CR32, SiR22, GeR22; R2 = H, (un)substituted
(cyclo)alkyl, aryl, etc.; R3 = R2, halo; D = O, S, PR4, etc.; R4 = H,
(un)substituted (cyclo)alkyl, alkenyl, etc.; n, z = 0, 1, 2, 3] are used
as catalysts for prep. of high-mol.-wt. poly-.alpha.-olefins. Thus,
polymn. of ethylene in the presence of (2-cyclopentadienyl-1-oxo-
ethanediyl)titaniun dichloride and methylalumoxanes gave a polymer with
intrinsic viscosity (in trichlorobenzene, 145.degree.) 3.5 dL/g.

IT 64723-42-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

L44 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 (organometallic catalysts for prepn. of high-mol.-wt.
 poly- α -olefins)
 RN 64723-43-9 CAPLUS
 CN 9H-Fluorene-9-ethanol, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


IT 200004-42-8 200004-44-0P 200004-51-9P
 200004-52-0P 200004-53-1P 200004-54-2P
 200004-55-3P 200004-56-4P 200004-58-6P
 200004-59-7P 200004-61-1P 200004-62-2P
 200004-66-6P 200004-67-7P 200004-70-2P
 200004-71-3P 200004-73-5P 200004-74-6P
 200004-75-7P 200004-76-8P 200004-77-9P
 200004-78-0P 200004-79-1P 200004-80-4P
 200004-81-5P 200004-84-8P 200004-87-1P
 200004-88-2P 200004-90-6P 200004-96-2P
 200005-05-6P 200005-07-8P 200005-08-9P
 200005-11-4P 200005-17-0P 200005-24-9P
 200005-32-9P 200005-34-1P 200005-41-0P
 200005-42-4P 200005-46-5P 200005-49-8P
 200005-51-2P 200005-52-3P 200005-54-5P
 200006-00-4P 200006-10-1P 200006-08-2P
 200006-09-3P 200006-10-6P 200006-24-2P
 200006-25-3P 200006-30-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prep. of amino acid derivs. as pharmaceuticals for treatment of neural. and neuropsychiatric disorders)

RN 200004-42-8 CAPLUS
 CN Glycine, N-(4,4-diphenyl-3-butenyl)-N-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 200004-44-0 CAPLUS
 CN Glycine, N-[2-(9H-fluoren-9-yl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-51-9 CAPLUS
 CN Glycine, N-methyl-N-[3,3,3-tris(4-fluorophenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)


applicants

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 ACCESSION NUMBER: 1997:803807 CAPLUS
 DOCUMENT NUMBER: 128:48490
 TITLE: Preparation of amino acid derivatives as pharmaceuticals for treatment of neurological and neuropsychiatric disorders
 INVENTOR(S): Ognyanov, Vassil Iliya; Borden, Laurence; Bell, Stanley Charles; Zhang, Jing
 PATENT ASSIGNEE(S): Trophix Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 107 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9745115	A1	19971204	WO 1997-US9450	19970529
W: AL, AM, AT, AU, AZ, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HV, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TN, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, IE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, HC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN				
CA 2254833	AA	19971204	CA 1997-2254833	19970529
AU 9731530	A1	19980105	AU 1997-31530	19970529
AU 730789	B2	20010315		
EP 1014966	A1	20000705	EP 1997-926971	19970529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 332780	A	20000728	NZ 1997-332780	19970529
BR 9709501	A	20001107	BR 1997-0501	19970529
CN 1327383	A	20011219	CN 1997-136921	19970529
JP 2002515037	T2	20020521	JP 1997-543034	19970529
NO 9805711	A	19981207	NO 1998-5711	19981207
PRIORITY APPLN. INFO.:				
US 1996-656912	A	19960531		
US 1996-656063	A	19960531		
US 1997-808754	A	19970227		
US 1997-808755	A	19970227		
US 1997-807682	A	19970227		
WO 1997-US9450	W	19970529		

OTHER SOURCE(S): MARPAT 128:48490
 AB Amino acid derivs. R₂R₃R₄XR₁NR₃(R₃)(CR₄R₄*R₅ [X = N, C (R₂ not present when X = N); R₂ = H, alkyl, alkoxy, cyano, alkancoyl, etc.; R₃, R₄, R₅ = aryl, heteraryl, adamantlyl, or nonarom. ring linked to X via a single bond, alkylene, etc.; R₁ = alkylene, iminoalkylene, etc.]; R₃ = H, alkyl, (un)substituted Ph or phenylalkyl, etc.; R₅ = alkyl, O- n = 0, 1; R₄, R₄* = H, alkyl, hydroxyalkyl; R₅* = (un)substituted carbamoyl, carboxy, aminosulfonyl, phosphoryl, etc.] were prep'd. as pharmaceuticals for treatment of neural. and neuropsychiatric disorders. Thus, N-(4-(4-diphenyl-3-butene)-glycine Et ester was by alkylation of glycine Et ester hydrochloride with 4-bromo-1,1-diphenyl-1-butene. Binding assays to measure interaction of compds. with the glycine site on the NMDA receptor


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-52-0 CAPLUS
 CN Glycine, N-(3-cyclohexyl-3-phenylpropyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-53-1 CAPLUS
 CN Glycine, N-methyl-N-(3,3,3-tris(4-methoxyphenyl)propyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-54-2 CAPLUS
 CN Glycine, N-[3,3-bis(3-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 RN 200004-55-3 CAPLUS
 CN Glycine, N-(3,5-diphenylpentyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-56-4 CAPLUS
 CN Glycine, N-(3,3-bis(4-phenoxyphenyl)propyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-58-6 CAPLUS
 CN Glycine, N-(3-(4-(1,1-dimethylethyl)phenyl)-3-phenylpropyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-59-7 CAPLUS
 CN Glycine, N-methyl-N-[3,3,3-tris(4-chlorophenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-61-1 CAPLUS


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN Glycine, N-methyl-N-[3-(2-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-62-2 CAPLUS
 CN Glycine, N-(3-(2-naphthalenyl)-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-66-6 CAPLUS
 CN Glycine, N-(3-[1,1'-biphenyl]-4-yl-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-67-7 CAPLUS
 CN Glycine, N-(3-[1,1'-biphenyl]-4-yl-3-phenylpropyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-70-2 CAPLUS
 CN Glycine, N-methyl-N-(3-phenyl-3-[4-(trifluoromethyl)phenyl]propyl)-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-71-3 CAPLUS
 CN Glycine, N-(3-phenyl-3-[4-(trifluoromethyl)phenyl]propyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-73-5 CAPLUS
 CN Glycine, N-[3-(4-(1,1-dimethylethyl)phenoxy)-3-(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-74-6 CAPLUS
 CN Glycine, N-methyl-N-[3-((6-methyl-3-pyridinyl)oxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-75-7 CAPLUS
 CN Glycine, N-[3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-76-8 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[4-(1,1,3,3-tetramethylbutyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-77-9 CAPLUS
 CN Glycine, N-[3-(3R)-3-((1,1'-biphenyl)-4-yloxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200004-78-0 CAPLUS
 CN Glycine, N-[3-(3S)-3-((1,1'-biphenyl)-4-yloxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 200004-79-1 CAPLUS
 CN Glycine, N-[3-(4-(1,1-dimethylethyl)phenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-80-4 CAPLUS
CN Glycine, N-methyl-N-[3-(4-phenyl-3-[4-(trifluoromethyl)phenoxy]phenoxy)propyl]-, ethyl ester (9CI) (CA INDEX NAME)





RN 200004-81-5 CAPLUS
CN Glycine, N-methyl-N-[3-(4-phenoxyphenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-84-8 CAPLUS
CN Glycine, N-[3-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-87-1 CAPLUS
CN Glycine, N-methyl-N-[3-(2-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-08-9 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-(4-methoxyphenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-11-4 CAPLUS
CN Glycine, N-methyl-N-[3R]-3-(4-nitrophenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200005-17-0 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200005-24-9 CAPLUS
CN Acetonitrile, (methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino)- (9CI) (CA INDEX NAME)


RN 200004-88-2 CAPLUS
CN Glycine, N-methyl-N-[3-(1-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-90-6 CAPLUS
CN Glycine, N-[3-((1,1'-biphenyl)-4-yloxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-96-2 CAPLUS
CN Glycine, N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-05-6 CAPLUS
CN Glycine, N-[3-(4-chlorophenyl)-3-(4-cyanophenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-07-8 CAPLUS
CN Glycine, N-[3-(4-chlorophenyl)-3-phenoxypropyl]-N-methyl-, ethyl ester




RN 200005-32-9 CAPLUS
CN Phosphonic acid, [(methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino)methyl]-, diethyl ester (9CI) (CA INDEX NAME)




RN 200005-34-1 CAPLUS
CN Glycine, N-(3,3-diphenylpropyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 200005-41-0 CAPLUS
CN Glycine, N-[3-hydroxy-3-phenyl-3-(2-thienyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-42-1 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(2-thienyl)-2-propenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-46-5 CAPLUS
CN Glycine, N-[3-(4-methoxyphenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN

(Continued)




RN 200005-49-8 CAPLUS
 CN Glycine, N-[3-[(4-(1,1-dimethylethyl)phenyl)thio]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-51-2 CAPLUS
 CN Glycine, N-[(3R)-3-[(4-(1,1-dimethylethyl)phenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 200005-52-3 CAPLUS
 CN Glycine, N-(4,4-diphenyl-3-butenyl)-N-ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-54-5 CAPLUS
 CN Glycine, N-(4,4-diphenylbutyl)-, ethyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



● HCl

RN 200006-09-3 CAPLUS
 CN Glycine, N-[(3R)-3-[(1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




● HCl

RN 200006-10-6 CAPLUS
 CN Glycine, N-[(3R)-3-(4-fluorophenyl)-3-(4-tricyclo[3.3.1.13,7]dec-1-ylphenoxy)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 RN 200006-00-4 CAPLUS
 CN Glycine, N-[3-(1-naphthalenyl)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 200006-07-1 CAPLUS
 CN Glycine, N-[(3S)-3-[(1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 200006-08-2 CAPLUS
 CN Glycine, N-[(3R)-3-[(1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200006-24-2 CAPLUS
 CN 2-Azetidinecarboxylic acid, 1-(4,4-diphenyl-3-butenyl)-, methyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200006-25-3 CAPLUS
 CN 2-Piperidinocarboxylic acid, 1-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-50-4 CAPLUS
 CN 2-Piperidinocarboxylic acid, 1-[3-(4-chlorophenyl)-3-(4-fluorophenyl)-3-hydroxypropyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 76991-05-4P 200004-41-7P 200004-45-1P
 200004-46-2P 200004-47-3P 200004-48-4P
 200004-49-5P 200004-50-8P 200004-57-5P
 200004-60-0P 200004-63-3P 200004-64-4P
 200004-65-5P 200004-69-9P 200004-72-4P
 200004-83-7P 200004-85-9P 200004-86-0P
 200004-89-3P 200004-91-7P 200004-92-8P
 200004-93-9P 200004-94-0P 200004-95-1P
 200004-97-3P 200004-98-4P 200004-99-5P
 200005-00-1P 200005-01-2P 200005-02-3P
 200005-03-4P 200005-04-5P 200005-06-7P
 200005-09-0P 200005-10-3P 200005-12-5P
 200005-13-6P 200005-14-7P 200005-15-8P
 200005-16-9P 200005-18-1P 200005-19-2P
 200005-21-6P 200005-22-7P 200005-23-8P
 200005-25-0P 200005-26-1P 200005-27-2P
 200005-28-3P 200005-29-4P 200005-30-7P
 200005-31-8P 200005-33-0P 200005-35-2P
 200005-36-3P 200005-37-4P 200005-38-5P
 200005-39-6P 200005-40-9P 200005-43-2P
 200005-44-3P 200005-45-4P 200005-47-6P
 200005-48-7P 200005-50-1P 200005-53-4P
 200005-55-6P 200005-56-7P 200005-57-8P
 200005-58-9P 200005-59-0P 200005-60-3P
 200005-61-4P 200005-62-5P 200005-63-6P
 200005-64-7P 200005-65-8P 200005-66-9P
 200005-67-0P 200005-68-1P 200005-69-2P
 200005-70-5P 200005-71-6P 200005-72-7P
 200005-73-8P 200005-74-9P 200005-75-0P
 200005-76-1P 200005-77-2P 200005-78-3P
 200005-79-4P 200005-80-5P 200005-81-6P
 200005-82-9P 200005-83-0P 200005-84-1P
 200005-85-2P 200005-86-3P 200005-87-4P
 200005-88-5P 200005-89-6P 200005-90-9P
 200005-91-0P 200005-92-1P 200005-93-2P
 200005-94-3P 200005-95-4P 200005-96-5P
 200005-97-6P 200005-98-7P 200005-99-8P
 200006-01-5P 200006-02-6P 200006-03-7P
 200006-04-8P 200006-05-9P 200006-06-0P
 200006-11-7P 200006-12-8P 200006-22-0P

200006-23-1P 200006-27-5P 200006-28-6P
 200006-29-7P 200006-30-0P 200006-31-1P
 200006-33-3P 200006-35-5P 200006-37-7P
 200006-39-9P 200006-40-2P 200006-42-4P
 200006-44-6P 200006-46-8P 200006-48-0P
 200006-52-6P 200006-54-8P 200006-56-0P
 200006-58-2P 200006-60-6P 200006-63-3P
 200006-85-5P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SWN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of amino acid derivs. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders)
 RN 76991-05-4 CAPLUS
 CN Acetamide, 2-[(3,3-diphenylpropyl)amino]- (9CI) (CA INDEX NAME)




RN 200004-41-7 CAPLUS
 CN L-Alanine, N-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200004-45-1 CAPLUS
 CN D-Alanine, N-(4,4-diphenyl-3-butenyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 200004-46-2 CAPLUS
 CN Glycine, N,N-bis[2-(9H-fluoren-9-yl)ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-47-3 CAPLUS
 CN Glycine, N-(4,4-bis(4-fluorophenyl)butyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200004-48-4 CAPLUS
 CN Glycine, N-[3,3-bis(4-fluorophenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-49-5 CAPLUS
 CN Glycine, N-(3-cyano-3,3-diphenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-50-8 CAPLUS
 CN Glycine, N-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200004-57-5 CAPLUS
 CN Glycine, N-[3,3-bis([1,1'-biphenyl]-4-yl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-60-0 CAPLUS
 CN Glycine, N,N-bis[3-(2-naphthalenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-63-3 CAPLUS
 CN Glycine, N-[3-(4-(1,1-dimethylethyl)phenyl)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-64-4 CAPLUS
 CN Glycine, N-methyl-N-(3,3-triphenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 RN 200004-65-5 CAPLUS
 CN Glycine, N,N-bis(3-[1,1'-biphenyl]-4-yl-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-69-9 CAPLUS
 CN Glycine, N-(3,4-diphenyl-3-butenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-72-4 CAPLUS
 CN Glycine, N-[3,3-bis(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-83-7 CAPLUS
 CN Glycine, N-[3-(4'-bromo[1,1'-biphenyl]-4-yl)oxy]-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-85-9 CAPLUS
 CN Glycine, N-methyl-N-[3-(3-phenyl-3-[3-(trifluoromethyl)phenoxy]propyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-93-9 CAPLUS
 CN Glycine, N-methyl-N-[3-[4-nitro-3-(trifluoromethyl)phenoxy]-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-94-0 CAPLUS
 CN Glycine, N-[3-(4-cyanophenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-95-1 CAPLUS
 CN Glycine, N-(3-phenoxy-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-97-3 CAPLUS
 CN Glycine, N,N-bis(3-phenyl-3-[4-(trifluoromethoxy)phenoxy]propyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-98-4 CAPLUS
 CN Glycine, N-[3-phenyl-3-[4-(trifluoromethoxy)phenoxy]propyl]-, ethyl ester


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-96-0 CAPLUS
 CN Glycine, N-[3-phenyl-3-[3-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200004-89-3 CAPLUS
 CN Glycine, N-methyl-N-[3-(4-methylphenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-91-7 CAPLUS
 CN Glycine, N-[3-(4-(aminosulfonyl)phenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200004-92-8 CAPLUS
 CN Glycine, N-methyl-N-[3-(4-nitrophenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-93-9 CAPLUS
 CN Glycine, N-methyl-N-[3-[4-nitro-3-(trifluoromethyl)phenoxy]-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200004-99-5 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethoxy)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-00-1 CAPLUS
 CN Glycine, N-[3-(2,4-dimethoxyphenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-01-2 CAPLUS
 CN Glycine, N-[3-(1,3-benzodioxol-5-yloxy)-3-(4-chlorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-02-3 CAPLUS
 CN Glycine, N-[3-(4-bromophenyl)-3-phenoxypropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-03-4 CAPLUS
 CN Glycine, N-[3-(4-bromophenyl)-3-[4-(trifluoromethyl)phenoxy]propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-04-5 CAPLUS
 CN Glycine, N-[3-(4-chlorophenyl)-3-(4-methoxyphenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-06-7 CAPLUS
 CN Glycine, N-[3-(4-bromophenyl)-3-(4-chlorophenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-09-0 CAPLUS
 CN Glycine, N-[3-(4-fluorophenyl)-3-phenoxypropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-14-7 CAPLUS
 CN Glycine, N-[(3R)-3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200005-15-8 CAPLUS
 CN Glycine, N-[(3R)-3-(4-fluorophenyl)-3-(4-tricyclo[3.3.1.13,7]dec-1-ylphenoxy)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 200005-16-9 CAPLUS
 CN Benzenepropanamine, gamma-((1,1'-biphenyl)-4-yloxy)-N-(2,2-dimethoxyethyl)-4-fluoro-N-methyl- (9CI) (CA INDEX NAME)




RN 200005-10-3 CAPLUS
 CN Glycine, N-[3-(4-fluorophenyl)-3-[4-(trifluoromethyl)phenoxy]propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-12-5 CAPLUS
 CN Glycine, N-[(3S)-3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 200005-13-6 CAPLUS
 CN Glycine, N-[(3R)-3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




RN 200005-18-1 CAPLUS
 CN Glycine, N-[2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)ethyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-19-2 CAPLUS
 CN Glycine, N-[(5H-dibenzo[a,d]cyclohepten-5-yl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-21-6 CAPLUS
 CN Glycine, N-[3-(9,10-ethanoanthracen-9(10H)-yl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-22-7 CAPLUS
 CN Glycine, N-[3-(2-methoxyphenoxy)-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-23-8 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, propyl ester (9CI) (CA INDEX NAME)




RN 200005-25-0 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 200005-26-1 CAPLUS
CN Acetamide, N-ethyl-2-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)




RN 200005-27-2 CAPLUS
CN Acetamide, N,N-diethyl-2-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)




RN 200005-28-3 CAPLUS
CN Glycine, N-methyl-N-[2-methyl-3-(1-oxopropoxy)-3,4-diphenylbutyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-35-2 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)



RN 200005-36-3 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, phenyloxymethyl ester (9CI) (CA INDEX NAME)




RN 200005-37-4 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, octyl ester (9CI) (CA INDEX NAME)




RN 200005-38-5 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 200005-39-6 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 200005-29-4 CAPLUS
CN Glycine, N-(3-hydroxy-2-methyl-3,4-diphenylbutyl)-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-30-7 CAPLUS
CN Acetamide, 2-[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]- (9CI) (CA INDEX NAME)




RN 200005-31-8 CAPLUS
CN Morpholine, 4-[[methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino]methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 200005-33-0 CAPLUS
CN Glycine, N-(3-(1-naphthalenyl)-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-40-9 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 200005-43-2 CAPLUS
CN Glycine, N-[3-(2-furanyl)-3-hydroxy-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-44-3 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(2-thienyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-45-4 CAPLUS
CN Glycine, N-methyl-N-[3-phenoxy-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-47-6 CAPLUS
CN Glycine, N-methyl-N-[3-phenyl-3-(phenylthio)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)


RN 200005-48-7 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[(4-(trifluoromethyl)phenyl)thio]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-50-1 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-(phenylamino)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-53-4 CAPLUS
 CN Glycine, N-(3,3-diphenylpropyl)-N-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 200005-55-6 CAPLUS
 CN Glycine, N-(4,4-diphenylbutyl)-N-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 200005-56-7 CAPLUS
 CN Glycine, N-(4,4-diphenylbutyl)-N-ethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-57-8 CAPLUS
 CN Glycine, N-(4,4-diphenyl-3-butenyl)-, hydrochloride (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

Ph2C=CH-CH2-CH2-NH-CH2-CO2H


● HCl

RN 200005-58-9 CAPLUS
 CN Glycine, N-(4,4-diphenylbutyl)-, hydrochloride (9CI) (CA INDEX NAME)

Ph2CH-(CH2)3-NH-CH2-CO2H


● HCl

RN 200005-59-0 CAPLUS
 CN Glycine, N-[3-((1,1'-biphenyl)-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-60-3 CAPLUS
 CN Glycine, N-(3-cyclohexyl-3-phenylpropyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

RN 200005-61-4 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[(4-(1,1,3,3-tetramethylbutyl)phenoxy)propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-62-5 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[(4-(trifluoromethyl)phenoxy)phenoxy]propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-63-6 CAPLUS
 CN Glycine, N-[3-[(4-(1-dimethylsilyl)phenoxy)-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-64-7 CAPLUS
 CN Glycine, N-[3-[(4'-cyano[1,1'-biphenyl]-4-yl)oxy]-3-phenylpropyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




● HCl

RN 200005-65-8 CAPLUS
 CN Glycine, N-methyl-N-[3-(3,3,3-tris(4-chlorophenyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-66-9 CAPLUS
 CN Glycine, N-methyl-N-[3-(2-naphthalenyl)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-67-0 CAPLUS
 CN Glycine, N-[3-((1,1'-biphenyl)-4-yloxy)-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-68-1 CAPLUS
 CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenyl]-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-69-2 CAPLUS
 CN Glycine, N-(3-[1,1'-biphenyl]-4-yl-3-phenylpropyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-70-5 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-(phenylthio)propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-71-6 CAPLUS
 CN Glycine, N-[3-(3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-72-7 CAPLUS
 CN Glycine, N-(3-[4-chlorophenyl]-3-(4-cyanophenoxy)propyl)-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-73-8 CAPLUS
 CN Glycine, N-[3-(4-chlorophenyl)-3-phenoxypropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-74-9 CAPLUS
 CN Glycine, N-methyl-N-[(3R)-3-(4-nitrophenoxy)-3-phenylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 200005-75-0 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-(4-(trifluoromethyl)phenoxy)propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-76-1 CAPLUS
 CN Glycine, N-[(3R)-3-[4-(1,1-dimethylethyl)phenoxy]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl


RN 200005-77-2 CAPLUS
 CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenylthio]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-78-3 CAPLUS
 CN Glycine, N-[(3R)-3-[(1,1'-biphenyl)-4-yloxy]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 200005-79-4 CAPLUS
 CN Glycine, N-methyl-N-[3-(4-phenoxyphenoxy)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-80-7 CAPLUS
 CN Glycine, N-[3,3-bis(4-phenoxyphenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-81-8 CAPLUS
 CN Glycine, N-methyl-N-[3-(1-naphthalenyl)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-82-9 CAPLUS
 CN Glycine, N-(3,5-diphenylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-86-3 CAPLUS
 CN Glycine, N-methyl-N-(3-phenoxy-3-phenylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-87-4 CAPLUS
 CN Glycine, N-[3-(4-cyanophenoxy)-3-phenylpropyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-88-5 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-(4-(trifluoromethyl)phenyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-89-6 CAPLUS
 CN Glycine, N-[3-(4-methoxyphenoxy)-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-83-0 CAPLUS
 CN Glycine, N-[3-(2-naphthalenyl)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-84-1 CAPLUS
 CN Glycine, N-methyl-N-[3-(4-nitro-3-(trifluoromethyl)phenoxy)-3-phenylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-85-2 CAPLUS
 CN Glycine, N-methyl-N-(3,3,3-triphenylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-90-5 CAPLUS
 CN Glycine, N-[3-(4-fluorophenyl)-3-(4-(trifluoromethyl)phenoxy)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-91-0 CAPLUS
 CN Glycine, N-methyl-N-[3-(2-naphthalenyl)-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-92-1 CAPLUS
 CN Glycine, N-[3-(4-(1,1-dimethylethyl)phenoxy)-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-93-2 CAPLUS
 CN Glycine, N-methyl-N-[3-[(6-methyl-3-pyridinyl)oxy]-3-phenylpropyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 200005-94-3 CAPLUS
 CN Glycine, N-methyl-N-[3,3,3-tris(4-methoxyphenyl)propyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 200005-95-4 CAPLUS

Absolute stereochemistry. Rotation (+).




● HCl

RN 200005-96-5 CAPLUS
 CN Glycine, N-[3,3-bis(3-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-97-6 CAPLUS
 CN Glycine, N-[3,3-bis((1,1'-biphenyl)-4-yl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 RN 200005-98-7 CAPLUS
 CN Glycine, N-[3-[4-(1,1-dimethylethyl)phenyl]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200005-99-8 CAPLUS
 CN Phosphonic acid, [(1methyl[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amino)methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-01-5 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[(4-(trifluoromethyl)phenyl)thio]propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-02-6 CAPLUS
 CN Glycine, N-methyl-N-[3-(4-nitrophenoxy)-3-phenylpropyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-03-7 CAPLUS
 CN Glycine, N-[(3-[(1,1'-biphenyl)-4-yl]-3-phenylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-04-8 CAPLUS
 CN Glycine, N-[3-phenyl-3-[4-(trifluoromethyl)phenyl]propyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-05-9 CAPLUS
 CN Glycine, N-[3-(4-fluorophenyl)-3-(4-methoxyphenoxy)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-06-0 CAPLUS
 CN Glycine, N-methyl-N-(3,3,3-tris(4-fluorophenyl)propyl)-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200006-11-7 CAPLUS
 CN 1H-1,2,4-Triazole-3-methanamine, N-(3,3-diphenylpropyl)-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 200006-12-8 CAPLUS



RN 200006-22-0 CAPLUS
 CN 2-Piperidinocarboxylic acid, 1-[4,4-bis(4-fluorophenyl)butyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-23-1 CAPLUS
 CN 2-Piperidinocarboxylic acid, 1-[2-(9H-fluoren-9-yl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-27-5 CAPLUS
 CN L-Proline, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 200006-28-6 CAPLUS
 CN 2-Piperidinocarboxylic acid, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-29-7 CAPLUS
 CN 2-Piperidinocarboxylic acid, 1-(3,3-diphenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-30-0 CAPLUS
 CN 2-Piperidinocarboxylic acid, 1-(3-cyano-3,3-diphenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-31-1 CAPLUS
 CN 2-Piperidinocarboxylic acid, 1-(4,4-diphenylbutyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-33-3 CAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-(3,3-diphenylpropyl)-, methyl ester, (1R,2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 200006-35-5 CAPLUS
 CN L-Proline, 1-(4,4-diphenyl-3-but enyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200006-37-7 CAPLUS
 CN 3-Azabicyclo[3.1.0]hexane-2-carboxylic acid, 3-(4,4-diphenyl-3-but enyl)-, methyl ester, (1R,2R,5S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 200006-39-9 CAPLUS
 CN 1H-Indole-2-carboxylic acid, 1-[2-(diphenylmethoxy)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200006-40-2 CAPLUS
 CN 2-Azetidinecarboxylic acid, 1-(4,4-diphenyl-3-butenyl)-, hydrochloride, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl


RN 200006-42-4 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-44-6 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[3,3-bis(4-fluorophenyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200006-56-0 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[3-(4-methoxyphenoxy)-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 200006-58-2 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[3-phenyl-3-(phenylthio)propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-60-6 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[3-(4-chlorophenyl)-3-hydroxy-3-phenylpropyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-83-3 CAPLUS
 CN Glycine, N-methyl-N-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 RN 200006-16-8 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-(3-hydroxy-3-diphenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-48-0 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[3-(4-chlorophenoxy)-3-phenylpropyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-52-6 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-54-8 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-(3-phenoxy-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200006-85-5 CAPLUS
 CN 2-Piperidinecarboxylic acid, 1-[3-(4-chlorophenyl)-3-(4-fluorophenyl)-2-phenylpropyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 101781-30-0 200004-38-2 200006-13-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prep. of amino acid derivs. as pharmaceuticals for treatment of
 neural. and neuropsychiatric disorders)

RN 101781-30-0 CAPLUS
 CN Benzenethanol, .alpha.-(1-methyl-2-(methylamino)ethyl)-.alpha.-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 200004-38-2 CAPLUS
 CN Benzene, 1,1',1'''-(bromomethylidyne)tris[4-fluoro- (9CI) (CA INDEX NAME)




RN 200006-13-9 CAPLUS

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CN 1-Naphthalenepropanamine, γ -phenyl- (9CI) (CA INDEX NAME)




IT 21763-01-9P 64723-43-9P 83584-90-1P
 200003-86-7P 200003-88-9P 200003-89-0P
 200003-90-3P 200003-91-4P 200003-92-5P
 200003-93-6P 200003-94-7P 200003-95-8P
 200003-96-9P 200003-97-0P 200003-98-1P
 200003-99-2P 200004-00-8P 200004-01-9P
 200004-02-0P 200004-03-1P 200004-04-2P
 200004-05-3P 200004-06-4P 200004-07-5P
 200004-08-6P 200004-09-7P 200004-10-0P
 200004-11-1P 200004-12-2P 200004-13-3P
 200004-14-4P 200004-15-5P 200004-16-6P
 200004-17-7P 200004-18-8P 200004-19-9P
 200004-20-2P 200004-22-4P 200004-23-5P
 200004-24-6P 200004-25-7P 200004-26-8P
 200004-27-9P 200004-28-0P 200004-29-1P
 200004-30-4P 200004-31-5P 200004-32-6P
 200004-33-7P 200004-34-8P 200004-35-9P
 200004-36-0P 200004-37-1P 200006-17-3P
 200006-20-8P 200006-21-9P 200006-72-0P
 200006-74-2P 200006-76-4P 200006-78-6P
 200006-80-0P
 RL: RCT (Reactant); SPA (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of amino acid derivs. as pharmaceuticals for treatment of
 neurol. and neuropsychiatric disorders)

RN 21763-01-9 CAPLUS
 CN Benzene, (3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)




RN 64723-43-9 CAPLUS
 CN 9H-Fluorene-9-ethanol, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)



RN 83584-90-1 CAPLUS
 CN Benzenepropanol, γ -phenyl-, γ -diphenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-86-7 CAPLUS
 CN Benzenepropanol, 4-fluoro-, γ -(4-fluorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-88-9 CAPLUS
 CN Benzenepropanol, 4-fluoro-, γ -(4-fluorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)

L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)

RN 200003-89-0 CAPLUS
 CN Benzenepropanol, γ -cyclohexyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-90-3 CAPLUS
 CN Benzenepropanol, 4-methoxy-, γ -(4-methoxyphenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-91-4 CAPLUS
 CN Benzenepropanol, 3-fluoro-, γ -(3-fluorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)


L44 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)




RN 200003-92-5 CAPLUS
 CN Benzenepentanol, γ -phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-93-6 CAPLUS
 CN Benzenepropanol, 4-phenoxy-, γ -(4-phenoxyphenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-94-7 CAPLUS
 CN [1,1'-Biphenyl]-4-propanol, γ -(1,1'-biphenyl)-4-yl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-95-8 CAPLUS
 CN Benzenepropanol, 4-(1,1-dimethylethyl)-, γ -phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-96-9 CAPLUS
CN Benzenepropanol, 4-chloro-, gamma-, gamma-bis(4-chlorophenyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-97-0 CAPLUS
CN 2-Naphthalenepropanol, .gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-98-1 CAPLUS
CN [1,1'-Biphenyl]-4-propanol, .gamma.-phenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200003-99-2 CAPLUS




RN 200004-00-8 CAPLUS
CN Benzenepropanol, .gamma.-phenyl-4-(trifluoromethyl)-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)




RN 200004-01-9 CAPLUS
CN Benzene, 1-[3-chloro-1-[4-(1,1-dimethylethyl)phenoxy]propyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 200004-02-0 CAPLUS
CN Pyridine, 5-(3-chloro-1-phenylpropoxy)-2-methyl- (9CI) (CA INDEX NAME)



RN 200004-03-1 CAPLUS
CN 1,1'-Biphenyl, 4-[3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX NAME)




RN 200004-04-2 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(1,1,3,3-tetramethylbutyl)- (9CI) (CA INDEX NAME)




RN 200004-05-3 CAPLUS
CN 1,1'-Biphenyl, 4-[(1R)-3-chloro-1-phenylpropoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 200004-06-4 CAPLUS
CN 1,1'-Biphenyl, 4-[(1S)-3-chloro-1-phenylpropoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 200004-07-5 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 200004-08-6 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-[4-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 200004-09-7 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-phenoxy- (9CI) (CA INDEX NAME)




RN 200004-10-0 CAPLUS
CN 1,1'-Biphenyl, 4-bromo-4'-(3-chloro-1-(4-fluorophenyl)propoxy)- (9CI) (CA INDEX NAME)




RN 200004-11-1 CAPLUS
CN [1,1'-Biphenyl]-4-carbonitrile, 4'-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 200004-12-2 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 200004-13-3 CAPLUS
CN Naphthalene, 2-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 20004-14-4 CAPLUS
CN Naphthalene, 1-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 20004-15-5 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-methyl- (9CI) (CA INDEX NAME)




RN 20004-16-6 CAPLUS
CN 1,1'-Biphenyl, 4-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 20004-17-7 CAPLUS
CN Benzenesulfonamide, 4-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 20004-18-8 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-nitro- (9CI) (CA INDEX NAME)




RN 20004-19-9 CAPLUS
CN Benzene, 4-(3-chloro-1-phenylpropoxy)-1-nitro-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 20004-20-2 CAPLUS
CN Benzonitrile, 4-(3-chloro-1-phenylpropoxy)- (9CI) (CA INDEX NAME)




RN 20004-22-4 CAPLUS
CN Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 20004-23-5 CAPLUS
CN Benzene, 1-[3-chloro-1-[4-(trifluoromethyl)phenoxy]propyl]-2,4-dimethoxy- (9CI) (CA INDEX NAME)




RN 20004-24-6 CAPLUS
CN 1,3-Benzodioxole, 5-[3-chloro-1-(4-chlorophenyl)propoxy]- (9CI) (CA INDEX NAME)




RN 20004-25-7 CAPLUS
CN Benzene, 1-bromo-4-(3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)




RN 20004-26-8 CAPLUS
CN Benzene, 1-bromo-4-(3-chloro-1-[(4-(trifluoromethyl)phenoxy)propyl])- (9CI) (CA INDEX NAME)




RN 20004-27-9 CAPLUS
CN Benzene, 1-chloro-4-(3-chloro-1-(4-methoxyphenoxy)propyl)- (9CI) (CA INDEX NAME)




RN 20004-28-0 CAPLUS
CN Benzonitrile, 4-[3-chloro-1-(4-chlorophenyl)propoxy]- (9CI) (CA INDEX NAME)




RN 20004-29-1 CAPLUS
CN Benzene, 1-bromo-4-[3-chloro-1-(4-chlorophenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 20004-30-4 CAPLUS
CN Benzene, 1-chloro-4-(3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)




RN 20004-31-5 CAPLUS
CN Benzene, 1-[3-chloro-1-(4-fluorophenyl)propoxy]-4-methoxy- (9CI) (CA INDEX NAME)




RN 20004-32-6 CAPLUS
CN Benzene, 1-(3-chloro-1-phenoxypropyl)-4-fluoro- (9CI) (CA INDEX NAME)




RN 200004-33-7 CAPLUS
CN Benzene, 1-[3-chloro-1-(4-fluorophenyl)propoxy]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 200004-34-8 CAPLUS
CN Benzene, 1-[{1R)-3-chloro-1-phenylpropoxy]-4-nitro- (9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (+).




RN 200004-35-9 CAPLUS
CN 1,1'-Biphenyl, 4-[(1S)-3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (-).




RN 200004-36-0 CAPLUS
CN 1,1'-Biphenyl, 4-[(1R)-3-chloro-1-(4-fluorophenyl)propoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




RN 200004-37-1 CAPLUS
CN Tricyclo[3.3.1.13,7]decane, 1-[4-((1R)-3-chloro-1-(4-fluorophenyl)propoxy)phenyl]- (9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (+).




RN 200006-17-3 CAPLUS
CN Glycine, N-methyl-N-[3-[(4-methylphenyl)sulfonyl]phenylamino]-3-phenylpropyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-20-8 CAPLUS
CN Acetonitrile, [(3,3-diphenylpropyl)amino]- (9CI) (CA INDEX NAME)




RN 200006-21-9 CAPLUS
CN Acetonitrile, [(3,3-diphenylpropyl)methylamino]- (9CI) (CA INDEX NAME)




RN 200006-72-0 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(3-oxo-3-phenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-74-2 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-[3-(4-fluorophenyl)-3-oxopropyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 200006-76-4 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(3-oxo-3-phenylpropyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 200006-78-6 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(3-hydroxy-3-phenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 200006-80-0 CAPLUS
CN 2-Piperidinocarboxylic acid, 1-(3-chloro-3-phenylpropyl)-, methyl ester (9CI) (CA INDEX NAME)



IT 200006-19-59
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of amino acid derivs. as pharmaceuticals for treatment of
neurul. and neuropsychiatric disorders)
RN 200006-19-5 CAPLUS
CN Benzenepropanaminium, N-(2-ethoxy-2-oxoethyl)-N,N-dimethyl-.gamma.-(4-(trifluoromethyl)phenoxy)-, iodide (9CI) (CA INDEX NAME)




● I⁻

ANSWER 8 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1982:598350 CAPLUS
 DOCUMENT NUMBER: 96:198350
 TITLE: Synthetic methods for alkyl(pyridine)cobaloximes: 3,3-triphenylpropyl- and 1-methylbut-3-ethyl(pyridine)cobaloxime
 AUTHOR(S): Ashcroft, Martin R.; Atkins, Martin P.; Golding, Bernard T.; Johnson, Michael D.; Sellers, Philip J.
 CORPORATE SOURCE: Dep. Chem., Univ. Coll., London, WC1H 0AJ, UK
 SOURCE: Journal of Chemical Research, Synopses (1982), (8), 216-17
 CODEN: JRPSCD; ISSN: 0308-2342
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 97:198350

AB 3,3-Triphenylpropyl(pyridine)cobaloxime was prep'd. in 60% yield by portionwise alternating addn. of solns. of NaBH₄ in EtOH and Ph₃C(CH₃)₂ in C₆H₆ to a soln. of bromo(pyridine)cobaloxime in EtOH under N₂. 1-Methylbut-3-ethyl(pyridine)cobaloxime, free of isomeric impurities, was prep'd. in 73% yield by stirring CoCl₂·6H₂O and dimethylglyoxime in MeOH under N₂ for 30 min., ice cooling, adding sequentially pyridine, 17.3M aq. NaOH, and 1-bromopentene, and stirring for 18 h.

IT 03594-90-1
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and reaction with sodium iodide)

RN 03594-90-1 CAPLUS
 CN Benzene propanol, .gamma.,.gamma.-diphenyl-, 4-methylbenzenesulfonate (9CI) (CA INDEX NAME)



ANSWER 10 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1982:35710 CAPLUS
 DOCUMENT NUMBER: 96:35710
 TITLE: Glycinamides
 INVENTOR(S): Van Dorsser, William; Martens, Mark; Gillet, Claude; Niebes, Paul; Roncucci, Romeo; Roba, Joseph; Cordi, Alexis; Lambelin, Georges
 PATENT ASSIGNEE(S): Continental Pharma, Belg.
 SOURCE: Belg., 57 pp.
 CODEN: BEXXAL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
 BE 005303 A1 198010319 BE 1980-202158 19800919
 PRIORITY APPLN. INFO.: BE 1980-202158 19800919
 AB RHN-CH₂CONR₂H (R = optionally alkyl, alkenyl, alkynyl, acyl; R₁ = H, alkyl, acyl, alkoxy carbonyl, H₂NC(=O)H; R₂ = H, alkyl, Ph, halo phenyl; R₃ = H, alkyl) were prep'd. Thus, Me(CH₂)₁₇NH₂ was treated with ClCH₂CONH₂ to give Me(CH₂)₁₇NHCH₂CONH₂ which was anticonvulsant against bicucullin-induced convolution in mice at 10-100 mg/kg orally.

IT 76991-05-4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. and anticonvulsant activity of)

RN 76991-05-4 CAPLUS
 CN Acetamide, 2-(3,3-diphenylpropyl)amino- (9CI) (CA INDEX NAME)



ANSWER 9 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 1982:142447 CAPLUS
 DOCUMENT NUMBER: 96:142447
 TITLE: Aryloxyphenylpropylamines
 INVENTOR(S): Molloy, Bryan B.; Schmiegel, Klaus K.
 PATENT ASSIGNEE(S): Lilly, Eli, and Co., USA
 SOURCE: U.S. 6 pp. Cont.-in-part of U.S. Ser. No. 872,148.
 CODEN: USXOAH
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4313896	A	19820202	US 1981-241913	19810309
US 4314081	A	19820202	US 1974-432379	19740110
AT 7602370	A	19761015	AT 1976-2370	19760401
AT 337161	B	19770610		
AT 7602371	A	19761015	AT 1976-2371	19760401
AT 337162	B	19770610		
CS 189638	P	19790430	CS 1977-248	19770114
CS 186397	P	19800331	CS 1977-7781	19771124


PRIORITY APPLN. INFO.: US 1974-432379 19740110
 US 1978-872148 19780125
 AT 1975-150 19750108
 CS 1975-150 19750108

AB p-F₃CC₆H₄OCHPhCH₂CH₂NH₂ (1) was prep'd. from PhCH₂CH₂CH₂Cl with p-F₃CC₆H₄ONa and Na₃N and redn. of the azide function with NaBH₄. The oxalic acid and HCl salts of 1 are also claimed. 1 is an antidepressant; data for the blocking of norepinephrine and serotonin uptake are given.

IT 21763-01-9
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and ammonolysis of)

RN 21763-01-9 CAPLUS

CN Benzene, (3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)



ANSWER 11 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1981:139256 CAPLUS
 DOCUMENT NUMBER: 94:139256
 TITLE: Glycinamide derivatives and their use
 INVENTOR(S): Roncucci, Romeo; Gillet, Claude; Cordi, Alexis; Martens, Mark; Roba, Joseph; Niebes, Paul; Lambelin, Georges; Van Dorsser, William
 PATENT ASSIGNEE(S): Continental Pharma, Belg.
 SOURCE: Ger. Offen., 89 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3010599	A1	19801009	DE 1980-3010599	19800320
DE 3010599	C2	198009302		
DE 3050800	C2	19800622	DE 1980-3050800	19800320
DK 8001235	A	19800923	DK 1980-1235	19800321
DK 162714	B	19911202		
DK 162714	C	19920421		
SE 4592204	A	19800923	SE 1980-2204	19800321
SE 453917	B	19800314		
SE 453917	C	19800623		
FI 8000900	A	19800923	FI 1980-900	19800321
FI 82033	B	19900928		
FI 82033	C	19910110		
NO 8000830	A	19800923	NO 1980-830	19800321
NO 157817	B	19800215		
NO 157817	C	19800525		
FR 2451913	A1	19801017	FR 1980-6390	19800321
FR 2451913	B1	19840713		
ES 490536	A1	19810416	ES 1980-490536	19800321
ZA 8001682	A	198010826	ZA 1980-1682	19800321
ZH 645091	A	19804914	ZH 1980-2253	19800321
IL 59679	A1	19841130	IL 1980-59679	19800321
AT 8001546	A	19860215	AT 1980-1546	19800321
AT 381302	B	19860925		
JP 55143944	A2	19801110	JP 1980-36806	19800322
JP 63009491	B4	19808229		
NL 8001721	A	19800924	NL 1980-1721	19800324
NL 191508	B	19950418		
NL 191508	C	19950821		
AU 8056784	A1	19800925	AU 1980-56784	19800324
AU 536499	B2	19840510		
GB 2048852	A	19801217	GB 1980-9801	19800324
GB 2048852	B2	19830330		
CA 1184567	A1	19850326	CA 1980-348319	19800324
AT 8402750	A	19900215	AT 1984-2750	19840828
AT 39134	B	19900827		
AT 8402751	A	19900815	AT 1984-2751	19840828
AT 392271	B	19910225		
US 4639468	A	19870127	US 1985-768185	19850823

PRIORITY APPLN. INFO.: LU 1979-81068 19790322
 LU 1979-81069 19790322
 AT 1980-1546 19800321
 US 1980-133102 19800324
 US 1983-485756 19830421


L44 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 AB The amides RNR1CH2CONR3R4 [I, R = C9-18 alkyl, C5-18 alkenyl, C4-10 alkynyl, C4-10 acyl, Cl-10 hydroxalkyl, alkoxycarbonylalkyl, acetoxyalkyl, carboxyalkyl, phenoxylalkyl, (un)substituted phenylalkyl; R1 = H, Cl-10 alkyl, Cl-6 acyl, Bz, Cl-4 alkoxyacetyl, carboxamidomethyl; R2 = H, Cl-3 alkyl, Ph; R3 = H, Cl-8 alkyl, halophenyl; R4 = H, Cl-8 alkyl] were prepd. Thus, Me(CH2)17NH2 was treated with ClCH2CONH2 to give Me(CH2)17NHCH2CONH2. I were tested for anticonvulsant activity in mice with bicuculline induced convulsions. The anticonvulsant ED50 of Me(CH2)4NHCH2CONH2 in mice was 11.2 mg/kg.

IT 76991-05-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (prepn. and anticonvulsant activity of)

RN 76991-05-4 CAPLUS

CN Acetamide, 2-[(3,3-diphenylpropyl)amino]- (9CI) (CA INDEX NAME)



L44 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 ACRSSION NUMBER: 1977:534520 CAPLUS
 DOCUMENT NUMBER: 87:134520
 TITLE: Aryloxyphenylpropylamines in treating depression
 INVENTOR(S): Molloy, Bryan B.; Schmiegel, Klaus K.
 PATENT ASSIGNEE(S): Lilly, Eli, and Co., USA
 SOURCE: U.S., 10 pp.
 CODEN: USXKAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4018895	A	19770419	US 1975-614094	19750917
US 4314081	A	19820202	US 1974-432379	19740110
AU 7476836	A1	19760624	AU 1974-76836	19741224
DK 7406889	A	19750901	DK 1974-6889	19741230
DK 140430	B	19790827		
DK 140430	C	19800121		
RO 69763	P	19820226	RO 1974-80996	19741230
RO 70660	P	19830926	RO 1974-90077	19741230
ZA 7500032	A	19760825	ZA 1975-32	19750102
CA 1051034	A1	19790320	CA 1975-217287	19750102
NL 7500186	A	19750714	NL 1975-186	19750107
NL 181654	B	19870504		
NL 181654	C	19871001		
CH 609331	A	19790228	CH 1978-2228	19750107
CH 609332	A	19790228	CH 1978-2229	19750107
CH 609675	A	19790315	CH 1975-102	19750107
AT 7500102	A	19760815	AT 1975-102	19750108
AT 336000	B	19770412		
CS 189680	P	19790430	CS 1975-150	19750108
BE 824255	A1	19750709	BE 1975-1006387	19750109
SE 7500215	A	19750711	SE 1975-215	19750109
SE 412906	B	19800324		
SE 412906	C	19800710		
FR 2257288	A1	19750808	FR 1975-543	19750109
GB 1493961	A	19771207	GB 1975-899	19750109
HU 173723	P	19790728	HU 1975-E1588	19750109
SU 1005655	A3	19830315	SU 1975-2101119	19750109
JP 50101333	A2	19750811	JP 1975-5888	19750110
JP 59039418	B4	19840922		
DD 118613	C	19760312	DD 1975-183594	19750110
ES 433720	A1	19761201	ES 1975-433720	19750110
PL 100330	P	19780930	PL 1975-177267	19750110
PL 101249	P	19781230	PL 1975-196995	19750110
PL 101229	P	19781230	PL 1975-196996	19750110
SU 583743	D	19771205	SU 1975-2302055	19751226
AT 7602370	A	19761015	AT 1976-2370	19760401
AT 337161	B	19770610		
AT 7602371	A	19761015	AT 1976-2371	19760401
AT 337162	B	19770610		
US 4194009	A	19800318	US 1976-723349	19760915
CS 189698	P	19790430	CS 1977-248	19770114
CS 196397	P	19800331	CS 1977-7781	19771124

L44 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 GS 196397 P 19800331 CS 1977-7781 19771124
 PRIORITY APPLN. INFO.: US 1974-432379 19740119
 AT 1975-102 19750108
 CS 1975-150 19750109

AB About 50 title amines, most of them of structure ROCR'NCH2CH2NR1Me (I; R = Ph, substituted phenyl, naphthyl; R1 = H, Me), or their salts, e.g., hydrochlorides, oxalates, and maleates, useful as psychotropics, particularly as antidepressants, were prepd. Thus, β -beta-(dimethylamino)propiophenone was reduced with diborane, the resultant alc. was chlorinated with SOC12-KCl in CHCl3, and the product was treated with p-F3CCG4ONa to give I (R = p-F3CCG4, R1 = Me). I blocked the uptake of physiol. active monoamines, such as serotonin and dopamine. Addnl. I showed activity in antagonizing hypothermia induced by apomorphine and activity in reversing reserpine hypothermia.


IT 21763-01-8P

RL: RCT (Reactant), RACT (Reactant or reagent)

(reaction of with ammonia)

RN 21763-01-9 CAPLUS

CN Benzene, (3-chloro-1-phenoxypyropyl)- (9CI) (CA INDEX NAME)




L44 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 ACRSSION NUMBER: 1975:592809 CAPLUS
 DOCUMENT NUMBER: 83:192809
 TITLE: 3-Aryloxy-3-phenylpropylamines
 INVENTOR(S): Molloy, Bryan B.; Schmiegel, Klaus K.
 PATENT ASSIGNEE(S): Lilly, Eli, and Co., USA
 SOURCE: Ger. Offen., 39 pp.
 CODEN: GWXKBX


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2500110	A1	19750717	DE 1975-2500110	19750103
DE 2500110	C2	19870611		
US 4314081	A	19820202	US 1974-432379	19740110
AU 7476836	A1	19760624	AU 1974-76836	19741224
DK 7406889	A	19750901	DK 1974-6889	19741230
DK 140430	B	19790827		
DK 140430	C	19800121		
RO 69763	P	19820226	RO 1974-80996	19741230
RO 70660	P	19800926	RO 1974-90077	19741230
ZA 7500032	A	19760825	ZA 1975-32	19750102
CA 1051034	A1	19790320	CA 1975-217287	19750102
NL 7500186	A	19750714	NL 1975-186	19750107
NL 181654	B	19800504		
NL 181654	C	19871001		
CH 609331	A	19790228	CH 1978-2228	19750107
CH 609332	A	19790228	CH 1978-2229	19750107
CH 609675	A	19790315	CH 1975-102	19750107
AT 7500102	A	19760815	AT 1975-102	19750108
AT 336000	B	19770412		
CS 189690	P	19790430	CS 1975-150	19750108
BE 824255	A1	19750709	BE 1975-1006387	19750109
SE 7500215	A	19750711	SE 1975-215	19750109
SE 412906	B	19800324		
SE 412906	C	19800710		
FR 2257288	A1	19750808	FR 1975-543	19750109
GB 1493961	A	19771207	GB 1975-899	19750109
HU 173723	P	19790728	HU 1975-E1588	19750109
SU 1005655	A3	19830315	SU 1975-2101119	19750109
JP 50101333	A2	19750811	JP 1975-5888	19750110
JP 59039418	B4	19840922		
DD 118613	C	19760312	DD 1975-183594	19750110
ES 433720	A1	19761201	ES 1975-433720	19750110
PL 100330	P	19780930	PL 1975-177267	19750110
PL 101249	P	19781230	PL 1975-196995	19750110
PL 101229	P	19781230	PL 1975-196996	19750110
SU 583743	D	19771205	SU 1975-2302055	19751226
AT 7602370	A	19761015	AT 1976-2370	19760401
AT 337161	B	19770610		
AT 7602371	A	19761015	AT 1976-2371	19760401
AT 337162	B	19770610		
US 4194009	A	19800318	US 1976-723349	19760915
CS 189698	P	19790430	CS 1977-248	19770114
CS 196397	P	19800331	CS 1977-7781	19771124

PRIORITY APPLN. INFO.: US 1974-432379 19740110
 AT 1975-102 19750108

L44 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN (Continued)
 CS 1975-150 19750108
 AB RCGH4OC(Ph)CH1CH2NR3R4 (I; R = H, F, 4-F3C, 3-Me2C, 2-MeO, etc.; R1, R2, R3, R4 = H, Me) were prep'd. Thus, PhCO(CH2)2NH2 was reduced by diborane to PhCH(OH)(CH2)2NH2, which reacted with HCl in CHCl3 to give PhCHCl(CH2)2NH2 (II). Reaction of II with 4-F3CCH4ONa gave I (R = 4-F3C, R1 = R2 = H; R3 = R4 = Me) which reacted with BrCN, then with KOH in HOCH2CH2OH to give I (R = 4-F3C, R1 = R2 = R3 = H, R4 = Me). I were useful as antidepressants; test data were given.
 IT 21763-01-9
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with ammonia)
 RN 21763-01-9 CAPLUS
 CN Benzene, (3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)



L44 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 CS 1972-48142 CAPLUS
 1972:48142 CAPLUS
 DOCUMENT NUMBER: 77:48142
 TITLE: Preparation of flavan by carbocyclization of
 .omega.-functional 1-phenoxy-1-phenylpropanes.
 Rearrangement leading to 4-phenylchroman
 AUTHOR(S): Silva, Monique; Silva, Henri; Maitte, Pierre
 CORPORATE SOURCE: Lab. Chim. XIV, Univ. Paris VI, Paris, Fr.
 SOURCE: Bulletin de la Societe Chimique de France (1972), (4),
 1540-4
 CODEN: BSCPAS; ISSN: 0037-8968
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 GI For diagram(s), see printed CA Issue.
 AB The cyclization of 1-phenoxy-1-phenylpropanes under either Friedel-Crafts or acidic conditions leads to 4-phenylchroman (I) rather than flavan (II) as expected. Thus, heating 3-chloro-1-phenoxy-1-phenylpropane in the presence of SnCl4 gives 25% I with large amounts of tar. The results are interpreted by cleavage of starting materials caused by attack of acid on the ether O to give a benzyl cation which adds electrophilically to the carbon alpha to the coupled O, followed by cycloelimination of halogen by the complexed O.
 IT 21763-01-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and cyclization of)
 RN 21763-01-9 CAPLUS
 CN Benzene, (3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)



L44 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2003 ACS on STN
 CS 1969:77711 CAPLUS
 1969:77711
 DOCUMENT NUMBER: 70:77711
 TITLE: Unexpected synthesis of 4-phenylchroman and a new
 preparation of flavan-3-ylcarbinols
 AUTHOR(S): Silva, Monique; Silva, Henri; Maitte, Pierre
 CORPORATE SOURCE: Lab. Chim. XIV, Fac. Sci., Paris, Fr.
 SOURCE: Comptes Rendus des Seances de l'Academie des Sciences,
 Serie C: Sciences Chimiques (1969), 268(3), 263-6
 CODEN: CHDCAQ; ISSN: 0567-6541
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 AB 1-Phenyl-1-phenoxy-3-chloropropane (I) is treated with SnCl4 at
 120.degree. and 1-phenyl-1-phenoxy-3-propanol (II) is treated with
 polyphosphoric acid at 90.degree. to give 4-phenylchroman (III). It is
 proposed that I and II react with Lewis acids (L) to give PhOL- (IV) and
 PhC=HCH2CH2X (V) intermediates and V add to IV in an electrophilic
 substitution to give III. o-Hydroxybenzyl alc. is treated with styrenes
 to give 3-(carboxy)flavan and 3-acetylflavan, which are converted to
 flavan-3-ylcarbinols.
 IT 21763-01-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 21763-01-9 CAPLUS
 CN Benzene, (3-chloro-1-phenoxypropyl)- (9CI) (CA INDEX NAME)

